STOCK TITAN

Evolus Inc - EOLS STOCK NEWS

Welcome to our dedicated news page for Evolus (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evolus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evolus's position in the market.

Rhea-AI Summary
Evolus, Inc. will report its Q3 2023 financial results and provide a business update on November 7, 2023. A conference call and webcast will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
conferences earnings
-
Rhea-AI Summary
Evolus to present final results from Phase 2 study at 2023 ASDS Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
-
Rhea-AI Summary
Evolus, Inc. grants stock options and restricted stock units to new employees under the 2023 Inducement Incentive Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Evolus, Inc. announces participation in two investment conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
conferences
-
Rhea-AI Summary
Evolus grants stock options and RSUs to new CMO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
-
Rhea-AI Summary
Evolus, Inc. appoints Tomoko Yamagishi-Dressler as CMO to drive growth and expand consumer base
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
-
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) reports Q2 2023 net revenue of $49.3 million, up 33% from Q2 2022, raising full-year 2023 net revenue guidance to $185 to $195 million. The company is on track to achieving sustained profitability with existing cash. President and CEO, David Moatazedi, highlighted the acceleration of trends and consistent execution of their long-term growth strategy, leading to record quarterly revenue and all-time highs across leading indicators.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Summary
Evolus, Inc. reported a net revenue of $49.3 million for Q2 2023, a 33% increase YoY, and raised its full-year revenue guidance to $185-$195 million. The company achieved record growth in new accounts and loyalty enrollments and redemptions. The CEO expressed confidence in the company's growth strategy and plans to expand the product portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.54%
Tags
Rhea-AI Summary
Evolus, Inc. to participate in Canaccord Genuity’s 43rd Annual Growth Conference in Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
conferences
Evolus Inc

Nasdaq:EOLS

EOLS Rankings

EOLS Stock Data

743.51M
38.80M
13.05%
77.11%
7.56%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Newport Beach

About EOLS

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.